Statins do not affect mineral metabolism in chronic kidney disease: A retrospective analysis

Nephron - Clinical Practice

Volumn 111, Issue 4, 2009, Pages

  Ashman, Neil ^a   Banerjee, Anindya ^b   Yaqoob, Muhammad M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ARROWE PARK HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Mineral metabolism; Statins

Indexed keywords

ALFACALCIDOL; ATORVASTATIN; CALCIUM; COLECALCIFEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; PHOSPHATE; SIMVASTATIN;

ADULT; ARTICLE; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDICATION; DRUG RECEPTOR BINDING; FEMALE; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

CALCIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALS; PHOSPHATES; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 61849124136     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000208992     Document Type: Article

References (13)

1. Tian J, Liu Y, Williams LA, de Zeeuw D: Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22: 321-328.
2. Grimes DS: Are statins analogues of vitamin D? Lancet 2006; 368: 83-86.
3. Marshall TG: Molecular genomics offers new insight into the exact mechanism of action of common drugs-ARBs, statins and corticosteroids. FDA CDER visiting professor presentation, FDA Biosciences Library, Accession QH447.M27, 2006.
4. Edwards CJ, Hart DJ, Spector TD: Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218-2219.
5. Yumita S, Suzuki M, Akiba T, et al: Levels of serum 1,25(OH) 2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med 1996; 180: 45-56.
6. Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
8. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl 5):v1-v52.
9. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Marshall TG, Lee RE, Marshall FE: Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3: 1.
11. Ide H, Fujiya S, Aanuma Y, Agishi Y: Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990; 12: 410-420.
12. Lozanoska-Ochser B, Barone F, Pitzalis C, Peakman M: Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes 2006; 55: 1004-1010.
13. Marshall TG: Are statins analogues of vitamin D? Lancet 2006; 368: 1234.